Status:
COMPLETED
Evaluation of the Effect of Telmisartan (Micardis® 80 mg/ MicardisPlus® 80/12.5 mg) on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Hypertension
Cardiovascular Diseases
Eligibility:
All Genders
18+ years
Brief Summary
The study is designed to evaluate the effect of treatment with Micardis/MicardisPlus on blood pressure and its ability to reduce different indicated cardiovascular risks. Further on, the study will ev...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- diagnosis of essential arterial hypertension (BP\>140/90 mm HG or BP\>130/80 mm Hg for diabetic patients)
- at least an additional cardiovascular risk factor
- Exclusion criteria:
- hypersensitivity to the active substance or to any of the excipients in any ACE inhibitor or angiotensin receptor blocker (ARB) available on the local market
- pregnancy and lactation
- diseases involving biliary obstruction
- severe liver impairment
Exclusion
Key Trial Info
Start Date :
December 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
211 Patients enrolled
Trial Details
Trial ID
NCT00904371
Start Date
December 1 2009
Last Update
August 21 2012
Active Locations (36)
Enter a location and click search to find clinical trials sorted by distance.
1
Boehringer Ingelheim Investigational Site 24
Brežice, Slovenia
2
Boehringer Ingelheim Investigational Site 2
Brežice, Slovenia
3
Boehringer Ingelheim Investigational Site 12
Celje, Slovenia
4
Boehringer Ingelheim Investigational Site 16
Celje, Slovenia